Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology.
Dr. Joshua Richter and Dr. Marco Davila discuss a case of a patient with relapsed/refractory multiple myeloma (RRMM) who has high-risk, rapidly progressive disease but faces practical barriers to receiving CAR T-cell therapy, including travel distance, caregiver availability, and time away from home.
Dr. Joshua Richter and Dr. Marco Davila discuss the importance of collaboration between specialized cellular therapy centers and community oncologists to improve access to CAR T-cell therapy for patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss how to prepare patients with relapsed/refractory multiple myeloma (RRMM) for the CAR T-cell therapy process by setting clear expectations before treatment begins.
Dr. Joshua Richter and Dr. Marco Davila discuss the importance of aligning treatment decisions with individual patient goals in relapsed/refractory multiple myeloma (RRMM), particularly among older adults being considered for CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the rationale for incorporating CAR T-cell therapy earlier in the treatment course for relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila present a case of a patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse after initial therapy and discuss whether patients considered ineligible for autologous stem cell transplantation may still be candidates for CAR T-cell therapy.
Dr. Joshua Richter discusses the rationale behind prioritizing BCMA-directed CAR T-cell therapy before BCMA-directed bispecific antibodies in eligible patients with multiple myeloma, reflecting current International Myeloma Working Group considerations.
Dr. Joshua Richter introduces the discussion with Dr. Doris Hansen, outlining the evolving role of CAR T-cell therapy in early relapsed/refractory multiple myeloma, with a focus on treatment sequencing, patient selection, bridging therapy, toxicity management, and emerging cellular therapies.
Dr. Joshua Richter and Dr. Marco Davila discuss the essential role of multidisciplinary care and caregiver engagement in the management of relapsed/refractory multiple myeloma (RRMM), particularly for patients undergoing CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss how to counsel patients with relapsed/refractory multiple myeloma (RRMM) about recovery and long-term follow-up after CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss practical strategies for bridging therapy in relapsed/refractory multiple myeloma (RRMM) as patients transition to CAR T-cell therapy.
Dr. Joshua Richter and Dr. Marco Davila discuss the ideal timing for referral to a cellular therapy specialist for patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Joshua Richter and Dr. Marco Davila discuss how clinicians determine the optimal timing for CAR T-cell therapy in relapsed/refractory multiple myeloma (RRMM), emphasizing that treatment decisions should be individualized rather than based solely on line of therapy.
Dr. Joshua Richter and Dr. Marco Davila examine how real-world evidence is shaping the use of CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) beyond the results of pivotal clinical trials.
Experts unpack relapsed myeloma sequencing—risk, refractoriness, and support—plus earlier CAR T and bispecifics shaping personalized care.
Experts unpack relapsed myeloma sequencing—risk factors, referrals, and earlier CAR‑T and bispecific therapies to personalize care and support patients.
Joshua Richter, MD, joins The Moonlight Shift to discuss the remarkable evolution of multiple myeloma treatment.
Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.
Joshua Richter, MD, elaborates on the best scenarios for certain CELMoD-based treatments for patients with multiple myeloma.
Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.
Joshua Richter, MD, discusses the FDA approval of linvoseltamab for relapsed or refractory multiple myeloma.
Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.
Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.
Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.
Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.
Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.
Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.
Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.
Ola Landgren, MD, PhD, leads the discussion on the use of cilta-cel and ide-cel in newly diagnosed multiple myeloma and the sequencing of available therapies in transplant-eligible and transplant-ineligible patients.
Experts discuss emerging BCMA-targeting CAR T-cell therapies under investigation for treating multiple myeloma and barriers to CAR T access.
December 22nd 2021
March 4th 2022
February 4th 2022
March 8th 2024
